2028 is going to be a landmark year in the pharmaceutical industry. Several blockbuster drugs, each with billion-dollar sales projections, will lose patent exclusivity, opening the door for Para IV filings.
For generic and biosimilar manufacturers, this represents a great opportunity. With the right data, the right timing, and tools like NCE Grid to track…
